Why MuGard Will Be Successful
Access Pharmaceuticals, Inc. (OTC:ACCP)
Many investors have raised concerns with regards to Access Pharmaceuticals being on the OTC. Indeed more than half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate investor demand. They will reach out to stock promoters, make deals with various PR companies and even go as far as releasing their own false press 
releases — usually involving buyouts (see OTC:PGYC). Folks, you need not worry, Access Pharma takes part in none of these illegal activities in order to induce demand, rather they focus on a solid and sound business strategy which willslowly take them into the promise land. Patience is a virtue.
MuGard is an interesting product with a lot of potential, and we truly believe that it is only a matter of time before this drug gains worldwide success from the ongoing marketing campaigns.
Oral Mucosis
Oral mucositis is a frequent complication of cancer chemotherapy or radiation therapy to the head and neck region. Currently available therapy is usually inadequate, and a more effective treatment to minimize the extent and duration of mucositis is clearly needed.
-
}Mucositis can affect most patients receiving cancer therapy.
-
Addressable market estimated at over $1 billion.
-
}MuGard is polymer solution which provides coating for oral cavity.
-
}Dispensed as a ready-to-use viscous liquid.
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
